BACKGROUND: Infection after severe trauma is a significant cause of morbidity and mortality days to weeks after the initial injury. Apolipoproteins play important roles in host defense and circulating concentrations are altered by the acute inflammatory response. The purpose of this study was to determine if patients who acquire infection after severe trauma have significantly lower apolipoprotein levels than trauma patients who do not become infected. METHODS: We conducted a case-control study on a prospectively identified cohort of adult patients admitted to our intensive care unit after severe trauma (Injury Severity Score ≥ 16). We compared plasma apolipoprotein levels between patients who acquired an infection within 30 days after trauma (cases) and those that remained infection free (controls). RESULTS: Of 40 patients experiencing severe trauma, we identified 22 cases that developed an infection within 30 days after injury. Cases had significantly lower posttrauma plasma levels of apolipoprotein B (p = 0.02) and apolipoprotein AII (p = 0.02) compared with controls. Consistent with previous studies, cases also received greater volumes of crystalloid infusions (p < 0.01) and blood transfusions (p < 0.01). Cases also had a more profound inflammatory response as measured by interleukin 6 levels (p = 0.02). CONCLUSION: Infection after severe trauma is associated with decreased circulating apolipoproteins as compared with uninfected controls. Profoundly decreased plasma apolipoproteins B and AII could potentially contribute to the impaired immunity after severe trauma. Apolipoproteins are potential targets for identifying those patients at risk of infection after trauma and for interventions aimed at preventing nosocomial infections. LEVEL OF EVIDENCE: Prognostic study, level III.
BACKGROUND:Infection after severe trauma is a significant cause of morbidity and mortality days to weeks after the initial injury. Apolipoproteins play important roles in host defense and circulating concentrations are altered by the acute inflammatory response. The purpose of this study was to determine if patients who acquire infection after severe trauma have significantly lower apolipoprotein levels than traumapatients who do not become infected. METHODS: We conducted a case-control study on a prospectively identified cohort of adult patients admitted to our intensive care unit after severe trauma (Injury Severity Score ≥ 16). We compared plasma apolipoprotein levels between patients who acquired an infection within 30 days after trauma (cases) and those that remained infection free (controls). RESULTS: Of 40 patients experiencing severe trauma, we identified 22 cases that developed an infection within 30 days after injury. Cases had significantly lower posttrauma plasma levels of apolipoprotein B (p = 0.02) and apolipoprotein AII (p = 0.02) compared with controls. Consistent with previous studies, cases also received greater volumes of crystalloid infusions (p < 0.01) and blood transfusions (p < 0.01). Cases also had a more profound inflammatory response as measured by interleukin 6 levels (p = 0.02). CONCLUSION:Infection after severe trauma is associated with decreased circulating apolipoproteins as compared with uninfected controls. Profoundly decreased plasma apolipoproteins B and AII could potentially contribute to the impaired immunity after severe trauma. Apolipoproteins are potential targets for identifying those patients at risk of infection after trauma and for interventions aimed at preventing nosocomial infections. LEVEL OF EVIDENCE: Prognostic study, level III.
Authors: Leslie Hoover; Grant V Bochicchio; Lena M Napolitano; Manjari Joshi; Kelly Bochicchio; Walter Meyer; Thomas M Scalea Journal: J Trauma Date: 2006-08
Authors: Alexis Tabah; Despoina Koulenti; Kevin Laupland; Benoit Misset; Jordi Valles; Frederico Bruzzi de Carvalho; José Artur Paiva; Nahit Cakar; Xiaochun Ma; Philippe Eggimann; Massimo Antonelli; Marc J M Bonten; Akos Csomos; Wolfgang A Krueger; Adam Mikstacki; Jeffrey Lipman; Pieter Depuydt; Aurélien Vesin; Maité Garrouste-Orgeas; Jean-Ralph Zahar; Stijn Blot; Jean Carlet; Christian Brun-Buisson; Claude Martin; Jordi Rello; Georges Dimopoulos; Jean-François Timsit Journal: Intensive Care Med Date: 2012-09-26 Impact factor: 17.440
Authors: Henk J van Leeuwen; Eric C J M Heezius; Geesje M Dallinga; Jos A G van Strijp; Jan Verhoef; Kok P M van Kessel Journal: Crit Care Med Date: 2003-05 Impact factor: 7.598
Authors: Brett C Manifold-Wheeler; Bradley O Elmore; Kathleen D Triplett; Moriah J Castleman; Michael Otto; Pamela R Hall Journal: J Immunol Date: 2015-11-25 Impact factor: 5.422
Authors: Michael D Ward; Ernst E Brueggemann; Tara Kenny; Raven E Reitstetter; Christopher R Mahone; Sylvia Trevino; Kelly Wetzel; Ginger C Donnelly; Cary Retterer; Robert B Norgren; Rekha G Panchal; Travis K Warren; Sina Bavari; Lisa H Cazares Journal: Clin Proteomics Date: 2019-02-07 Impact factor: 3.988